Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS (HIK)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/25 05:35:22 pm
1346.5 GBp   +0.52%
05/18HIKMA PHARMACEU : AGM Results
PU
05/18Hikma reaffirms full-year revenue forecast, cites better generics..
RE
05/18HIKMA PHARMACEU : Proxy Statments
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : AGM Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 02:14pm CEST

Hikma Pharmaceuticals PLC

Voting Results of 2018 Annual General Meeting

LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the 'Company') announces its Annual General Meeting ('AGM'), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.

As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1.To receive the 2017 report and accounts

196,394,230

99.96

72,200

0.04

196,466,430

245,708

2.To approve a final dividend of 23 cents per share

196,485,553

99.89

225,796

0.11

196,711,349

788

3.To re-appoint PricewaterhouseCoopers LLP as auditors

196,099,742

99.69

610,679

0.31

196,710,421

1,717

4.To authorise the Audit Committee to determine the auditors' remuneration

196,703,625

100.00

5,721

0.00

196,709,346

2,792

5.To elect Siggi Olafsson as a director

195,815,999

99.55

894,642

0.45

196,710,641

1,497

6.To re-elect Said Darwazah as a director

190,417,700

96.80

6,298,814

3.20

196,716,514

1,622

7.To re-elect Mazen Darwazah as a director

193,925,828

98.58

2,783,900

1.42

196,709,728

2,410

8.To re-elect Robert Pickering as a director

190,879,517

98.02

3,848,509

1.98

194,728,026

1,984,111

9.To re-elect Ali Al-Husry as a director

195,245,623

99.26

1,464,293

0.74

196,709,916

2,222

10.To re-elect Patrick Butler as a director

193,317,043

98.28

3,393,072

1.72

196,710,115

2,022

11.To re-elect Dr. Jochen Gann as a director

195,107,616

99.19

1,602,499

0.81

196,710,115

2,022

12. To re-elect John Castellani as a director

193,529,031

98.38

3,180,885

1.62

196,709,916

2,222

13. To re-elect Dr. Pamela Kirby as a director

190,289,183

96.74

6,421,682

3.26

196,710,865

1,272

14. To re-elect Nina Henderson as a director

192,848,157

98.04

3,862,508

1.96

196,710,665

1,472

15.To approve the remuneration report for the year ended 31 December 2017

169,750,519

86.36

26,815,358

13.64

196,565,877

146,261

16.To approve and adopt the 2018 Management Incentive Plan

195,620,834

99.45

1,088,481

0.55

196,709,315

2,822

17.Authority to allot shares

166,598,638

84.69

30,112,333

15.31

196,710,971

1,167

18. To dis-apply pre-emption rights for general purposes

196,660,802

99.97

50,469

0.03

196,711,271

867

19.To dis-apply pre-emption rights for an acquisition or other capital investment

195,530,359

99.40

1,179,711

0.60

196,710,070

2,067

20.To authorise the Company to purchase its own shares

195,989,881

99.68

621,703

0.32

196,611,584

100,553

21.To authorise the Company to hold general meetings on no less than 14 clear days' notice

187,831,722

95.49

8,878,028

4.51

196,709,750

2,388

Declaration of final dividend

The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3521 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs

Company Secretary

+44 20 7399 2670

Susan Ringdal

VP for Investor Relations and Strategy

+44 20 7399 2670

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

LEI: 549300BNS685UXH4JI75

Disclaimer

Hikma Pharmaceuticals plc published this content on 18 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 May 2018 12:13:08 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
05/18HIKMA PHARMACEUTICALS : AGM Results
PU
05/18Hikma reaffirms full-year revenue forecast, cites better generics business
RE
05/18HIKMA PHARMACEUTICALS : Press Release
CO
05/18HIKMA PHARMACEUTICALS : Proxy Statments
CO
04/30HIKMA PHARMACEUTICALS : Monthly statement on outstanding equity shares and votin..
CO
04/27HIKMA PHARMACEUTICALS : expands licensing agreement with Rovi for their enoxapar..
AQ
04/27HIKMA PHARMACEUTICALS : Princess Ghida Talal Opens Hikma's Annual Forum for the ..
AQ
04/26HIKMA PHARMACEUTICALS : Crossing thresholds
CO
04/25HIKMA PHARMACEUTICALS : Block listing Interim Review
PU
04/22HIKMA PHARMACEUTICALS : organizes ' Cancer Network - Middle East and North Afric..
AQ
More news
News from SeekingAlpha
04/15Longleaf Partners Shareholder Letter Q1 2018 
03/14Hikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnin.. 
03/14Hikma Pharmaceuticals reports FY results 
2017Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2017 Results - Earning.. 
2017Hikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 1 911 M
EBIT 2018 308 M
Net income 2018 185 M
Debt 2018 438 M
Yield 2018 1,77%
P/E ratio 2018 23,05
P/E ratio 2019 20,41
EV / Sales 2018 2,50x
EV / Sales 2019 2,34x
Capitalization 4 340 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 16,6 $
Spread / Average Target -7,5%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS18.74%4 340
JOHNSON & JOHNSON-11.45%327 893
PFIZER-1.16%209 941
NOVARTIS-6.94%193 872
ROCHE HOLDING LTD.-9.17%190 404
MERCK AND COMPANY5.08%159 078